RxDoctor Payments Data

John Nelson, MD

Internal Medicine · Fresno, CANPI 1003908591

Payments from drug & device makers

$412,561in general payments, 2019–2025

Across 866 payments — averaging $476.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$239K
  • Amgen$90K
  • Lilly USA, LLC$32K
  • Boehringer Ingelheim$26K
  • Esperion Therapeutics, Inc.$18K
  • Regeneron Healthcare Solutions, Inc.$4K
  • plus $3K from 18 others
$2,874in research payments, 2019–2025

Across 1 payment — averaging $2874.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$3K

What the payments were for

  • Consulting fees$13,1253%
  • Speaking & faculty fees$325,23179%
  • Travel & lodging$58,76614%
  • Food & beverage$15,4394%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$412,561 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$313,666
Medicare patients
426
Services billed
3,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab511$628,614
VascepaIcosapent Ethyl429$341,499
NexlizetBempedoic Acid/Ezetimibe177$153,785
Icosapent Ethyl332$136,222
EntrestoSacubitril/Valsartan65$91,907
EliquisApixaban64$64,470
XareltoRivaroxaban44$49,465
FarxigaDapagliflozin Propanediol29$37,405
Pitavastatin Calcium85$34,898
Ezetimibe932$33,892
LivaloPitavastatin Calcium26$23,985
Repatha SyringeEvolocumab13$18,103
Praluent PenAlirocumab18$16,923
EdarbiAzilsartan Medoxomil40$16,703
EdarbyclorAzilsartan Med/Chlorthalidone27$15,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Esperion Therapeutics, Inc.Nexlizet$17,585$153,785177 claims
NovartisEntresto$831$91,90765 claims
PfizerEliquis$78$64,47064 claims
Johnson & JohnsonXarelto$18$49,46544 claims
AstraZenecaFarxiga$364$37,40529 claims
Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor$105$31,81167 claims
Kowa Pharmaceuticals America, Inc.Livalo$846$23,98526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →